title: Correction of lysosomal dysfunction as a therapeutic strategy for neurodegenerative diseases.
abstract: Mutations in the gene that encodes the lysosomal enzyme acid β-glucosidase lead to reduced cellular activity and accumulation of glycosphingolipid substrates, biochemical hallmarks of the lysosomal storage disorder Gaucher disease (GD). Recently such mutations have been identified as risk factors for Parkinson's disease (PD) and related disorders. Both gain-of-function (due to toxic cellular accumulation of mutant enzyme) and loss-of-function (due to accumulation of lipid substrates) hypotheses have been put forth to address the biochemical link between GD and PD. Similarly, links between Alzheimer's disease and other lysosomal enzyme deficiencies have begun to emerge. The use of pharmacological chaperones to restore the cellular trafficking and activity of mutant lysosomal enzymes may offer a novel approach to treat these debilitating neurodegenerative diseases.
authors.affiliation: Amicus Therapeutics, 1 Cedar Brook Dr., Cranbury, NJ 08512, United States. Electronic address: rboyd@amicusrx.com.
authors.forename: Robert E
authors.initials: RE
authors.lastname: Boyd
authors.affiliation: Amicus Therapeutics, 1 Cedar Brook Dr., Cranbury, NJ 08512, United States.
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Valenzano
mesh_terms: D055808:Drug Discovery; D005962:Glucosylceramidase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008247:Lysosomes / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D009154:Mutation; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D005962:Glucosylceramidase
keywords: Gcase; Lysosomal dysfunction; Neurodegeneration